NCT01583686: A reported trial by National Cancer Institute (NCI)
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT01583686 |
|---|---|
| Title | Phase I/II Study of Metastatic Cancer Using Lymphodepleting Conditioning Followed by Infusion of Anti-mesothelin Gene Engineered Lymphocytes |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | May 4, 2012 |
| Completion date | Dec. 17, 2018 |
| Required reporting date | Dec. 17, 2019, midnight |
| Actual reporting date | Aug. 29, 2019 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |